Deloitte: Be purposeful in defining your work

Get to Work

Workers think in terms of projects, not long-term employment. 10'000 Hours/Getty Images

Not that long ago, employees had a defined role at a consistent worksite for the same company for many years. The employer-employee relationship seemed stable and well-defined. But times have changed. In a recent Deloitte Insights article, "What is the Future of Work?," Deloitte highlights how "forces of change" — e.g., accelerating connectivity, new talent models, artificial intelligence, crowdsourcing, etc. — are radically redefining the who, what, and where of work.

The workforce of the future has significant implications for everyone. For employees, planning out a 50-year career is almost impossible. For employers, their traditional approach to attract, develop, and retain workers has been shaken. The focus now is accessing and establishing flexible work engagements around specific projects. Deloitte's insights, summarized below, are eye-opening and portend potentially significant societal impact.

What is work?
Deloitte notes that technological advances have long impacted the nature of work in the Western world. The chart below shows the evolution across three eras.

Source: Deloitte Insights

In today's postindustrial era, robots and automated systems are replacing some jobs. Yet workers need not fear: their relational skills and insights can't be replaced by technology — and, in fact, enhance the value offered by technology. For example, online juggernaut Amazon opened a tech hub in Houston in July 2019. As the name implies, the hub will use technology, but it will also create 150 jobs, per a recent InnovationMap article. This is just one example illustrating that work now focuses on the ability to capture value from technology, solve problems, and manage human relationships.

Who is working?
The relationship between employers and employees will likely never be the same. Per Deloitte Insights, "[o]rganizations now have a broad continuum of options for finding workers, from hiring traditional full-time employees to availing themselves of managed services and outsourcing, independent contractors, gig workers, and crowdsourcing." This means companies should be adept at recruiting, engaging, and retaining workers in new types of relationships.

Workers in Houston are wading into the new model. In a study profiled in a recent CultureMap article, "Houston ranked second statewide and 11th in the U.S. among major metro areas for the size of the skilled-freelancer workforce per revenue produced." The relationship between workers and their jobs is shifting from long-term employment to project engagement.

Where are people working?
One thing is clear: workers are spending less face time with work colleagues. More and more work is being accomplished from home or coworking spaces. Many workers appreciate the flexibility of working remotely; companies can benefit from reduced overhead.

Houston is experiencing huge growth in the number of coworking spaces. The Cannon Houston moved into its new 120,000 square foot building in July 2019, and WeWork is planning to open another location, which will be its fourth in Houston and second in downtown Houston. These spaces offer not just desks and offices, but a variety of events and programming designed to foster community.

The new frontier
Deloitte notes that the full impact of these changes may just be starting — and the future of work is not a "foregone conclusion." We can allow technology to merely "drive more efficiency and cost reduction, or we can consider more deeply the ways to harness these trends and increase value and meaning across the board — for businesses, customers, and workers." Deloitte urges organizations to "zoom out and imagine the possibilities" to create positive outcomes for work, the workforce, and the workplace. As Deloitte sums it up: "[p]urpose will bring the future into focus."

---

This publication contains general information only and Deloitte is not, by means of this publication, rendering accounting, business, financial, investment, legal, tax, or other professional advice or services. This publication is not a substitute for such professional advice or services, nor should it be used as a basis for any decision or action that may affect your business. Before making any decision or taking any action that may affect your business, you should consult a qualified professional advisor. Deloitte shall not be responsible for any loss sustained by any person who relies on this publication.

About Deloitte
Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee ("DTTL"), its network of member firms, and their related entities. DTTL and each of its member firms are legally separate and independent entities. DTTL (also referred to as "Deloitte Global") does not provide services to clients. In the United States, Deloitte refers to one or more of the US member firms of DTTL, their related entities that operate using the "Deloitte" name in the United States and their respective affiliates. Certain services may not be available to attest clients under the rules and regulations of public accounting. Please see www.deloitte.com/about to learn more about our global network of member firms.

Ad Placement 300x100

Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Rice University leader balances tradition with innovation to drive growth, global impact

houston innovator podcast Episode 263

How does a historic university maintain its legacy while still making room for growth and increased opportunities? That's what Rice University President Reginald DesRoches considers with every decision he makes.

"It's this idea of preserving what's special about the university, while also knowing we need to adapt to a new time, a new Rice, a new time in higher ed, and a new time in society," DesRoches says on the Houston Innovators Podcast. "There's a healthy tension between preserving what Rice is known for — the culture of care, the close-knit community — while knowing that we need to grow, have a global impact, and position Rice on a global scale. It's something that's constantly in my mind to make sure we do both."

The school is undergoing an exciting growth period under the leadership of DesRoches, who was announced as Rice's eighth president in 2021. DesRoches says the university, which previously had a student body of 4,000 students a few years ago, has grown to 4,800 and will soon be at 5,200 — about a 30 percent growth in a short amount of time.

But the growth isn't just happening at the student level. Last year, Rice onboarded 97 faculty, which was about twice as many new hires the school would usually have in a year.

With these additions, the Rice campus is undergoing several construction projects to keep up with the growth. All of this is part of the school's strategic plan and road map, which DesRoches unveiled in October.

"The tagline is 'personalized scale for global impact,'" DesRoches shares. "We talk about our vision to be excellent in both teaching and research in the plan.

"Rice will be the world premiere teaching and research university delivering unparalleled personalized education and propelling breakthrough discoveries to transform lives and better humanity," he continues. "That's what we view as our mission and vision for the university."

DesRoches shares on the podcast how this bigger vision of leading global impact has translated to new research institutions — like the Rice Biotech Launch Pad and RBL LLC — and even global campuses in Paris and now India.

He also talks through the evolution of the Ion, which falls under the university's Office of Innovation umbrella.

New CEO brings strategic vision to Houston co. advancing neurodegenerative disease treatments

Q&A

Coya Therapeutics has named a new CEO. As of Nov. 1, Arun Swaminathan replaced Co-founder Howard Berman in the role. Berman has assumed the title of executive chairman, in which he will still remain active with the company.

Swaminathan started with Coya two years ago as chief business officer. This transition was planned, says the PhD-holding scientist and businessman.

“(Berman's) intent was that it was the right time to put in place a CEO that, as we move into the operational phases of the company, that can take the reins from him,” he tells InnovationMap.

Coya Therapeutics is a publicly traded biotechnology company that is working on two novel treatments for Alzheimer's disease. Coya's therapeutics, which are currently in trials, use regulatory T cells (T regs) to target both systemic- and neuroinflammation in patients.

InnovationMap: Berman has been a very visible CEO. Will you follow suit?

Arun Swaminathan: I think it's part of the CEO’s job to be visible and to communicate the value of our company to all the stakeholders out there. So yes, I do plan to be visible as well. Obviously, Howard as the founder had elements that he talked about, the foundational stories. I obviously will be doing less of that.

IM: What was your journey from the lab to the boardroom?

AS: I have a PhD from the University of Pittsburgh. I like to say that I grew up at Bristol Myers Squibb, so I started in a clinical pharmacology group at BMS, running clinical trials, but in the cardiovascular and metabolic space.

What happened was, as I was the study director on a diabetes trial there, and the data starts coming in for these early diabetic trials, and I got highly involved with the commercial folks at BMS in starting to plan out “What does the target profile look like? How is this going to play out in the real world?” You know, the marketing teams and commercial teams start engaging when clinical data is available, because they're starting to plan for the eventual launch of the product.

That gave me a lot of exposure to the commercial side of things, and I also got a lot of experience presenting to opinion leaders and others through that role. And I said, “What I really love is that intersection between science and business.” And so I think that was my moment.

Then I moved to business development and licensing, where I helped scan the universe for assets and talk to CEOs of companies like Coya as a junior person, trying to understand if there's something that we can bring into BMS to strengthen the pipeline of BMS. So that gave me exposure to deals, how deals are structured, how you negotiate a lot of that kind of stuff.

Then I said, “Look, if I want to be a complete person in biotech, I do need to go into more true commercial roles.” So I went into commercial strategy. I was involved in the commercial strategy for what is now known as Eliquis. Was back then known as apixaban. That’s still the generic name.

Then I led marketing for Orencia, a rheumatoid arthritis drug. So I went and got both strategic and tactical marketing experience at BMS, and then I used all of that experience, rounded up. I eventually ended up co-founding a company, and that's led me to the last nine years with smaller biotech companies. So that's my evolution and path. But I think my true moment of realization was about three years into my clinical role at BMS, when I said, what I really enjoy is translating good science into commercial value, and I think that's what excites me.

IM: Why is Houston an important part of Coya's success?

AS: It is important that Coya stays in Houston, because we have a very close association with Houston Methodist, we get a lot of our work, our early research work still done through Houston Methodist, through Dr. [Stanley] Appel's lab and through other experts. We absolutely have a special research agreement with Houston Methodist, so we have a very strong reason to be in Houston. So, we do not anticipate moving out of Houston.

------

This conversation has been edited for brevity and clarity.

California femtech leader integrates Houston-founded conversational AI tool

girl gang

Willow users, meet Ema — you're new best AI-enabled friend.

Houston-founded Ema (née SocialMama), an AI resource for maternal health support, has been loaded onto the Willow Innovations Inc. app, a platform for breastfeeding mothers.

"We are thrilled to integrate our conversational AI platform into the Willow App and leverage the power of advanced technology to meet women where they are with the information they need," Amanda Ducach, founder of Ema, says in a news release. "Ema and Willow have a shared mission to make lasting improvements in women's health and we built a one-of-a-kind solution that addresses the unique challenges mothers face regularly.

"Our partnership represents a critical advancement for today's mothers and demonstrates how responsible AI can improve the maternal care experience," she continues.

Now, users on the app can utilize Ema's HIPPA-secure tool that pulls from a comprehensive, proprietary database of expert-backed information. The conversational AI chatbot responds prioritizing speed, accuracy, and empathy and compassion for users. Ema reports that their users "will feel like they are talking with their favorite postpartum (labor and delivery) nurse."

"New moms don't have enough support — for their feeding and parenting journey, or in their postpartum care. We're thrilled to partner with Ema to offer moms personalized information along this journey," adds Sarah O'Leary, CEO of Willow. "AI tools, when implemented thoughtfully, can help close gaps in delivering personalized guidance at an efficient scale and I'm excited about the impact Ema can have on the well-being of mothers in our Willow community."

Founded in 2018 as a way to connect new moms, Ema evolved with a major rebrand and pivot to AI-backed tools last year.

Willow was launched in 2014 and released the first wearable, in-bra breast pump in 2017.

View All Listings

INNOVATIONMAP EMAILS ARE AWESOME